FDA regulatory chief to retire; Clean Air violations to cost Pfizer;

> Margaret O'Keefe Glavin, a top U.S. Food and Drug Administration official whose sizeable bonuses were among those criticized by lawmakers last year will retire soon, according to an internal agency memo sent Monday. Report

> Pfizer will pay $975,000 to settle alleged violations of the Clean Air Act at a former manufacturing plant in Groton, Conn. Report

> Novo Nordisk got the FDA nod for PrandiMet, a fixed-dose combination of the fast-acting insulin secretagogue repaglinide and metformin for the treatment of type 2 diabetes. Release

> Unichem Laboratories said it has received FDA approval for its plant in Uttar Pradesh, India; the company makes drug ingredients and some bulk meds. Report

> Orchid Chemicals & Pharmaceuticals won permission from Canadian drug regulators to sell a combination antibiotic piperacillin-tazobactam injection. Report

> Stiefel Laboratories is buying Barrier Therapeutics - a developer of dermatology products - in a deal valued at $148 million. Report

> Seattle-based Immune Design has raised an impressive $18 million in its first round of venture capital. VC report

> BusinessWeek's Gene Marcial sized up BioSante Pharmaceutical's pipeline and concluded that its late stage therapy for sexual dysfunction in menopausal women could make it a prime candidate for a buyout. BioSante report

> British biotech executives are sour on industry's 'dire' shape. Report

> Shares of GTC Therapeutics shot up after the company announced it had inked a $257 million licensing deal with Ovation Pharmaceuticals for its blood clotting therapy ATryn. Report

And Finally... You've heard of drug-resistant germs; now there's drug-resistant high blood pressure. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.